OncoHost's platform combines proteomic analysis with AI to predict host responses to immunotherapy, and gain insight into cancer treatments.

Oncohost developed a platform to identify key biological processes and proteins that drive response in patients undergoing cancer treatment.

OncoHost, an Israeli company using response profiling to improve personalized cancer therapy, announced last week it has opened a new state-of-the-art high throughput proteomics laboratory for analysis of host response to cancer treatment. Proteomics, or proteomic analysis, refers to the systematic identification and quantification of the complete complement of proteins (the proteome) of a biological […]